Skip to main content
Erschienen in: Die Onkologie 9/2009

01.09.2009 | Leitthema

Erkrankungsorientierte individuelle postoperative Therapie für Patientinnen mit Endometriumkarzinom

verfasst von: S. Uccella, S.C. Dowdy, A. Mariani, M.D.

Erschienen in: Die Onkologie | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den Industrieländern ist das Endometriumkarzinom (EK) das häufigste Malignom des weiblichen Genitaltrakts und die vierthäufigste Krebsart bei Frauen. Zum allgemein akzeptierten Management des Endometriumkarzinoms gehören die radikale Hysterektomie, die Entfernung der Adnexe und ein angemessenes operatives Staging der Patientinnen, bei denen das Risiko eines extrauterinen Karzinoms besteht. Im vorliegenden Beitrag werden die möglichen Indikationen für eine individuelle, erkrankungsorientierte postoperative Therapie bei Patientinnen mit Endometriumkarzinom diskutiert. Relevante Themen hierzu sind: Wege der lymphatischen Ausbreitung und operatives Staging bei EK, Definition verschiedener Arten der metastatischen Ausbreitung von EK, Einführung in das Konzept der erkrankungsbasierten postoperativen Therapie sowie die Entwicklung von Leitlinien für die postoperative Therapie von endometrioiden Endometriumkarzinomen auf der Basis von Erfahrungen mit der erkrankungsorientierten Therapie und retrospektiven Studien.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
3.
Zurück zum Zitat Podratz KC, Mariani A, Webb MJ (1998) Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol 70:163–164CrossRefPubMed Podratz KC, Mariani A, Webb MJ (1998) Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol 70:163–164CrossRefPubMed
4.
Zurück zum Zitat Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65CrossRefPubMed Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65CrossRefPubMed
5.
Zurück zum Zitat Rotman M, Aziz H, Halpern J et al (1993) Endometrial carcinoma. Influence of prognostic factors on radiation management. Cancer 71:1471–1479PubMed Rotman M, Aziz H, Halpern J et al (1993) Endometrial carcinoma. Influence of prognostic factors on radiation management. Cancer 71:1471–1479PubMed
7.
Zurück zum Zitat Thigpen JT, Blessing JA, DiSaia PJ et al (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12:1408–1414PubMed Thigpen JT, Blessing JA, DiSaia PJ et al (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12:1408–1414PubMed
8.
Zurück zum Zitat Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:3902–3908CrossRefPubMed Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:3902–3908CrossRefPubMed
9.
Zurück zum Zitat Aapro MS, van Wijk FH, Bolis G et al (2003) Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14:441–448CrossRefPubMed Aapro MS, van Wijk FH, Bolis G et al (2003) Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14:441–448CrossRefPubMed
10.
Zurück zum Zitat Fleming GF, Brunetto VL, Cella D et al (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166CrossRefPubMed Fleming GF, Brunetto VL, Cella D et al (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166CrossRefPubMed
11.
Zurück zum Zitat Randall ME, Filiaci VL, Muss H et al (2006) Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44CrossRefPubMed Randall ME, Filiaci VL, Muss H et al (2006) Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44CrossRefPubMed
12.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC et al (2000) PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 355:1404–1411CrossRefPubMed Creutzberg CL, van Putten WL, Koper PC et al (2000) PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 355:1404–1411CrossRefPubMed
13.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL et al (2000) Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 182:1506–1519CrossRefPubMed Mariani A, Webb MJ, Keeney GL et al (2000) Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 182:1506–1519CrossRefPubMed
14.
Zurück zum Zitat Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC et al (2004) Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22:1234–1241CrossRefPubMed Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC et al (2004) Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22:1234–1241CrossRefPubMed
15.
Zurück zum Zitat The writing committee on behalf of the ASTEC study group (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRef The writing committee on behalf of the ASTEC study group (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRef
16.
Zurück zum Zitat Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRef Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRef
17.
Zurück zum Zitat Cragun JM, Havrilesky LJ, Calingaert B et al (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675CrossRefPubMed Cragun JM, Havrilesky LJ, Calingaert B et al (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675CrossRefPubMed
18.
Zurück zum Zitat Kilgore LC, Partridge EE, Alvarez RD et al (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56:29–33CrossRefPubMed Kilgore LC, Partridge EE, Alvarez RD et al (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56:29–33CrossRefPubMed
19.
Zurück zum Zitat Mariani A, Webb MJ, Galli L et al (2000) Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76:348–356CrossRefPubMed Mariani A, Webb MJ, Galli L et al (2000) Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76:348–356CrossRefPubMed
20.
Zurück zum Zitat Trimble EL, Kosary C, Park RC (1998) Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 71:340–343CrossRefPubMed Trimble EL, Kosary C, Park RC (1998) Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 71:340–343CrossRefPubMed
21.
Zurück zum Zitat Uccella S, Podratz KC, Aletti GD et al (2009) Lymphadenectomy in endometrial cancer. Lancet 373:1170–1171 author replyCrossRefPubMed Uccella S, Podratz KC, Aletti GD et al (2009) Lymphadenectomy in endometrial cancer. Lancet 373:1170–1171 author replyCrossRefPubMed
22.
Zurück zum Zitat Creasman WT, Morrow CP, Bundy BN et al (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60:2035–2041CrossRefPubMed Creasman WT, Morrow CP, Bundy BN et al (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60:2035–2041CrossRefPubMed
23.
Zurück zum Zitat Mariani A, Keeney GL, Aletti G et al (2004) Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol 92:833–838CrossRefPubMed Mariani A, Keeney GL, Aletti G et al (2004) Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol 92:833–838CrossRefPubMed
24.
Zurück zum Zitat Mariani A, Dowdy SC, Cliby WA et al (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18CrossRefPubMed Mariani A, Dowdy SC, Cliby WA et al (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18CrossRefPubMed
25.
Zurück zum Zitat Podczaski E, Kaminski P, Gurski K et al (1992) Detection and patterns of treatment failure in 300 consecutive cases of „early“ endometrial cancer after primary surgery. Gynecol Oncol 47:323–327CrossRefPubMed Podczaski E, Kaminski P, Gurski K et al (1992) Detection and patterns of treatment failure in 300 consecutive cases of „early“ endometrial cancer after primary surgery. Gynecol Oncol 47:323–327CrossRefPubMed
26.
Zurück zum Zitat Aalders J, Abeler V, Kolstad P et al (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427PubMed Aalders J, Abeler V, Kolstad P et al (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427PubMed
27.
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMed Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMed
28.
Zurück zum Zitat Mariani A, Dowdy SC, Keeney GL et al (2005) Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol 97:820–827CrossRefPubMed Mariani A, Dowdy SC, Keeney GL et al (2005) Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol 97:820–827CrossRefPubMed
29.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL et al (2001) Hematogenous dissemination in corpus cancer. Gynecol Oncol 80:233–238CrossRefPubMed Mariani A, Webb MJ, Keeney GL et al (2001) Hematogenous dissemination in corpus cancer. Gynecol Oncol 80:233–238CrossRefPubMed
30.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL et al (2002) Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 87:274–280CrossRefPubMed Mariani A, Webb MJ, Keeney GL et al (2002) Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 87:274–280CrossRefPubMed
31.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL et al (2002) Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 84(3):437–442CrossRefPubMed Mariani A, Webb MJ, Keeney GL et al (2002) Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 84(3):437–442CrossRefPubMed
32.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL et al (2003) Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol 89:236–242CrossRefPubMed Mariani A, Webb MJ, Keeney GL et al (2003) Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol 89:236–242CrossRefPubMed
33.
Zurück zum Zitat Mariani A, Dowdy SC, Keeney GL (2004) High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 95:120–126CrossRefPubMed Mariani A, Dowdy SC, Keeney GL (2004) High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 95:120–126CrossRefPubMed
Metadaten
Titel
Erkrankungsorientierte individuelle postoperative Therapie für Patientinnen mit Endometriumkarzinom
verfasst von
S. Uccella
S.C. Dowdy
A. Mariani, M.D.
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 9/2009
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-009-1682-4

Weitere Artikel der Ausgabe 9/2009

Die Onkologie 9/2009 Zur Ausgabe

Einführung zum Thema

Endometriumkarzinom

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.